TSHA

Taysha Gene Therapies, Inc.

TSHA · CIK 1806310 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$8M
20202024
Net Income−$89M
20202024
Operating CF−$81M
20202024
Free Cash Flow−$82M
20202024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Revenue$0.0B$0.0B$0.0B——
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.1B$0.1B$0.1B$0.1B$0.0B
SG&A Expense—————
Operating Income$-0.1B$-0.1B$-0.2B$-0.2B$-0.0B
Net Income$-0.1B$-0.1B$-0.2B$-0.2B$-0.1B
EPS (Basic)$-0.36$-0.96$-3.78——
EPS (Diluted)$-0.36$-0.96$-3.78——

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Total Assets$0.2B$0.2B$0.1B$0.2B$0.3B
Current Assets$0.1B$0.1B$0.1B$0.2B$0.3B
Cash & Equivalents$0.1B$0.1B$0.1B$0.1B$0.3B
Total Liabilities$0.1B$0.1B$0.1B$0.1B$0.0B
Current Liabilities$0.0B$0.0B$0.1B$0.1B$0.0B
Stockholders' Equity$0.1B$0.1B$0.0B$0.1B$0.3B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕
Operating Cash Flow$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.1B$0.1B$0.1B$0.0B$0.3B
← Companies